Stay updated with breaking news from Real Time Barometer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
In an effort to push back against the still-ongoing global COVID-19 pandemic, Merck, in partnership with Ridgeback Biotherapeutics, is touting the benefits of an investigational oral antiviral medication known as molnupiravir, saying it reduces the risk of hospitalization and death among people with mild-to-moderate cases of the coronavirus.
PRESS RELEASE FROM SERMO Global Efforts to Stop the Spread of COVID-19 Undermined by Vaccine Side Effect Concerns Posted May 20, 2021 Global Efforts to Stop the Spread of COVID-19 Undermined by Vaccine Side Effect Concerns Insights from Sermo’s COVID-19 Real Time Barometer Survey point toward disease becoming endemic and need for more effective patient education New York, NY – May, 20 2021 - As the rate of people receiving COVID-19 vaccinations has slowed, a new survey of physicians has revealed that doctors are working hard to combat vaccine hesitancy, eve...
Two out of Three Do Not Believe or Are Unsure Whether the U.S. and World Will Return to Normal Following Vaccine Rollout NEW YORK, January 26, 2021 / B3C newswire / -- One year after the first COVID-19 case in the U.S., Sermo surveyed physicians around the world as part of its COVID-19 Real Time Barometer, revealing that 86% of doctors around the world believe that mental health issues and depression will be the biggest non-COVID-19 public health issue after the pandemic. Other areas of concern for the coming year are an increase in violence (34%), increase in spousal or child abuse (27%), in...